Chart Of The Week: Eurozone Credit Risk

Includes: EZU, FEZ, FXE, HEDJ, VGK
by: Topdown Charts

Eurozone credit risk pricing is starting to stir.

Arguably corporate credit risk pricing is too complacent, particularly relative to sovereign credit risk pricing.

Typically flareups in Eurozone risk pricing take at least a couple of months to run their course, so it's too soon to call the all clear on this one.

This week it's a look at credit risk pricing in the Eurozone. This is a chart I've been using a lot in recent months; of course, as of the last week, it's looking a bit more interesting now! The reason why I've highlighted this chart in the past is that post-financial crisis, sovereign credit risk pricing did calm down, but to a new plateau. In contrast, corporate credit risk pricing just got back to business down to pre-crisis lows.

The chart comes from a report on Eurozone equities, where I discussed the revised outlook based on changing signals from valuation, risk pricing, economic sentiment, and the earnings/macro backdrop. I think this chart is certainly one of the key risk monitor charts investors should have on their radar.

Briefly, on the actual detail, the black line is European high yield credit spreads, and the blue line is the spread between the benchmark Eurozone 10-year government bond yield and that of Germany. For both indicators, I have taken the Z-Score in order to standardize them and put them on a comparable scale.

The reason I think this chart is so important is firstly I would say that European high yield credit risk pricing is simply too complacent at these levels. We know that obviously the ECB played a part here in that QE purchases of corporate bonds have artificially suppressed credit spreads. But the key is the relative aspect (corporate credit looks too relaxed vs. sovereign credit risk pricing). And the final point to note, tactically speaking, is that flareups in these indicators can take some time to play through, so it's probably too soon to call the all clear on the current flareup.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.